United Therapeutics (NASDAQ:UTHR) EVP Sells $4,517,690.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,587,119.60. This represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Down 1.5%

UTHR stock traded down $8.39 during mid-day trading on Friday, reaching $533.12. 654,280 shares of the stock traded hands, compared to its average volume of 557,193. United Therapeutics Corporation has a 52 week low of $409.07 and a 52 week high of $609.35. The business has a 50-day moving average of $513.75 and a two-hundred day moving average of $540.45. The firm has a market capitalization of $22.87 billion, a PE ratio of 19.07, a P/E/G ratio of 3.86 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same period last year, the business posted $6.41 earnings per share. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.40 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on UTHR. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a report on Thursday, October 1st. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $677.00 to $708.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $368.00 target price on shares of United Therapeutics in a research note on Thursday. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $642.69.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in United Therapeutics in the 2nd quarter valued at approximately $2,868,735,000. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $450,140,000. Bank of New York Mellon Corp acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $159,522,000. Caisse de depot et placement du Quebec acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $154,304,000. Finally, Legal & General Group Plc acquired a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $112,209,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.